7,746 results match your criteria: "Cardiovascular Research Institute Maastricht; Medtronic Bakken Research Center Maastricht[Affiliation]"
Eur J Heart Fail
November 2024
Centre for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Clin Transl Sci
November 2024
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Nat Med
November 2024
Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of Clinical Science, Lund University, Helsingborg, Sweden.
Eur Respir J
November 2024
Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium.
Background: We conducted a volume-outcome (V-O) meta-analysis of PEA procedures for chronic thromboembolic pulmonary hypertension (CTEPH), to objectively determine the minimum required annual case load that can define a high-volume centre.
Methods: Three electronic databases were systematically queried until May 1st, 2024. Centres were divided in volume tertiles (Ts).
Thromb Res
January 2025
School for Cardiovascular Disease (CARIM), Maastricht University, the Netherlands; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands. Electronic address:
Background: The MR CLEAN NO-IV trial showed neither superiority nor noninferiority of endovascular treatment (EVT) alone compared to intravenous thrombolysis (IVT; Alteplase) before EVT in acute ischemic stroke (AIS) patients with large vessel occlusion of the anterior circulation. Although the treatment effect is largely attributable to EVT, IVT may affect hypercoagulability during AIS.
Aims: To investigate the association between activated coagulation and final infarct volume and clinical outcomes (modified Rankin Scale 3-6 and mortality 90 days post-EVT), and whether this effect is modified by IVT administration.
Objective: Children in families with parental cancer may experience emotional, social or physical problems. The aims are to analyze child, parent and family-based determinants of children's health-related quality of life (HRQoL) and their experiences of parental cancer.
Methods: As part of a mixed-methods, multicenter, prospective, interventional non-randomized study "Family-SCOUT," a family-centered intervention in the form of care and case management was developed.
Diabetes
February 2025
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.
Circ Cardiovasc Qual Outcomes
November 2024
Department of Cardiology, Amsterdam Cardiovascular Sciences Heart Failure and Arrhythmias, Amsterdam University Medical Centers Location University of Amsterdam, Heart Center, the Netherlands (R.E.K., J.A.d.V., L.V.A.B., T.F.B., S.P., A.-F.B.E.Q., L.S., W.v.d.S., A.d.W., J.R.d.G., K.M.K., J.G.P.T., A.A.M.W., L.R.A.O.N.).
Neth Heart J
December 2024
Department of Cardiology, Bernhoven Hospital, Uden, The Netherlands.
Eur Heart J
December 2024
Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, Maastricht 6229 HX, The Netherlands.
Front Bioeng Biotechnol
November 2024
Mosa Meat BV, Maastricht, Netherlands.
Introduction: To bring cultivated beef to the market, a scalable system that can support growth of bovine satellite cells (bSCs) in a serum-free and preferably also animal-free medium is of utmost importance. The use of microcarriers (MCs) is, at the moment, one of the most promising technologies for scaling up. MCs offer a large surface to volume ratio, they can be used in scalable stirred tank bioreactors, where the culture conditions can be tightly controlled to meet the cells' requirements (temperature, pH, dissolved oxygen).
View Article and Find Full Text PDFAnn Neurol
November 2024
Brain Research Imaging Center, Center for Clinical Brain Sciences, UK Dementia Institute Center at the University of Edinburgh, Edinburgh, UK.
Lancet
November 2024
Leipzig Heart Science, Leipzig, Germany; Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Leipzig, Germany. Electronic address:
Cardiogenic shock is a complex syndrome defined by systemic hypoperfusion and inadequate cardiac output arising from a wide array of underlying causes. Although the understanding of cardiogenic shock epidemiology, specific subphenotypes, haemodynamics, and cardiogenic shock severity staging has evolved, few therapeutic interventions have shown survival benefit. Results from seminal randomised controlled trials support early revascularisation of the culprit vessel in infarct-related cardiogenic shock and provide evidence of improved survival with the use of temporary circulatory support in selected patients.
View Article and Find Full Text PDFEur J Radiol
December 2024
Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands; Mental Health and Neuroscience Research Institute (MHeNs), University Maastricht, Maastricht, the Netherlands.
Background: Both CT angiography and CT perfusion involve the administration and tracking of a contrast medium bolus for different purposes. In this study, we aim to compare the diagnostic accuracy and subjective image quality of CTP-angiographic reconstructions with conventional CTA for occlusion detection in ischemic stroke patients.
Methods: In this retrospective study, patients with a final diagnosis of ischemic stroke and who underwent both CTA and CTP from September 2020 up to and including September 2021 were included.
Eur J Nutr
November 2024
Department of Nutrition and Movement Sciences, Research Institute of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University, Maastricht, The Netherlands.
Sci Rep
November 2024
Department for Biosciences of Sports, Institute of Sport Science, University of Hildesheim, Hildesheim, Germany.
J Clin Epidemiol
November 2024
Department of Intensive Care Medicine, Maastricht University Medical Center + (Maastricht UMC+), Maastricht, The Netherlands; Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands; Department of Epidemiology, Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands.
Background And Objectives: Mortality prediction models are promising tools for guiding clinical decision-making and resource allocation in intensive care units (ICUs). Clearly specified predictor and outcome variables are necessary to enable external validation and safe clinical application of prediction models. The objective of this study was to identify the predictor and outcome variables used in different mortality prediction models in the ICU and investigate their reporting.
View Article and Find Full Text PDFJACC Adv
November 2024
Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Background: Vital exhaustion, defined as excessive fatigue, demoralization, and irritability due to chronic stress, is independently associated with cardiovascular disease (CVD).
Objectives: The purpose of this study was to examine the association of vital exhaustion with biomarkers associated with CVD risk in the ARIC (Atherosclerosis Risk In Communities) study.
Methods: We examined the cross-sectional association of vital exhaustion (assessed using the Maastricht Vital Exhaustion Questionnaire [MVEQ]) with cardiac biomarker (high-sensitivity troponin T [hs-TnT], N-terminal pro-B-type natriuretic peptide [NT-proBNP]) and high-sensitivity C-reactive protein (hs-CRP) levels in 11,542 ARIC study participants without CVD at ARIC visit 2 using multivariable logistic and linear regression models.
Eur Heart J Cardiovasc Pharmacother
November 2024
Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Aims: A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function allele from ticagrelor or prasugrel to clopidogrel, has shown to reduce bleeding risk without affecting effectivity of therapy by increasing ischemic risk. We estimated the cost-effectiveness of this personalized approach compared to standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel) in the Netherlands.
Methods And Results: We developed a one-year decision tree based on results of the FORCE-ACS registry, comparing a cohort of ACS patients who underwent genotyping with a cohort of ACS patients treated with standard DAPT.
Kardiol Pol
January 2025
Department of Cardiac Surgery and Transplantology, National Medical Institute of the Ministry of Interior and Administration, Warszawa, Poland.
Front Cell Dev Biol
October 2024
Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians University Munich, Munich, Germany.
JACC Basic Transl Sci
October 2024
Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
The molecular mechanisms contributing to large artery stiffness (LAS) are not fully understood. The aim of this study was to investigate the association between circulating plasma proteins and LAS using complementary proteomic and genomic analyses. A total of 106 proteins associated with carotid-femoral pulse-wave velocity, a noninvasive measure of LAS, were identified in 1,178 individuals from the Asklepios study cohort.
View Article and Find Full Text PDFOsteoporos Int
January 2025
Department of Internal Medicine, VieCuri Medical Centre, P.O. Box 1926, 5900 BX, Venlo, The Netherlands.
Cardiovasc Res
November 2024
Istituto Cardiocentro Ticino, Laboratories for Translational Research, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Background And Aims: Cardiac fibrosis in response to injury leads to myocardial stiffness and heart failure. At the cellular level, fibrosis is triggered by the conversion of cardiac fibroblasts (CF) into extracellular matrix-producing myofibroblasts. miR-24-3p regulates this process in animal models.
View Article and Find Full Text PDFEur J Heart Fail
November 2024
Clinic for Electrophysiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany.
Aims: Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heart failure (HF). Cardiovascular mortality, driven by sudden cardiac death, is the main reason for dying while waiting for heart transplantation (HTx). The purpose of the Preventive Catheter Ablation for ventricular arrhythmiaS in patients with end-sTage heart faiLure rEferred for heart transplantation eValuaTion (CASTLE-VT) trial is to test the hypothesis that prophylactic catheter ablation of arrhythmogenic ventricular scar tissue will reduce mortality, need for LVAD implantation, and urgent HTx in patients with end-stage HF related to ischaemic cardiomyopathy (ICM).
View Article and Find Full Text PDF